Contact
searchSearch
HMP Global

Clinical Integration Topic Center

Ana Kiess, MD, PhD, Johns Hopkins Medicine
Videos
Personalizing Theranostics: Adaptive Dosing Strategies Informed by Radiation Oncology
02/12/2026
Ana Kiess, MD, PhD
Ana Kiess, MD, PhD, Johns Hopkins Medicine, Baltimore, Maryland, discusses how lessons from external beam radiation therapy can guide adaptive dosing strategies in theranostics to improve tumor control while balancing toxicity.
Ana Kiess, MD, PhD, Johns Hopkins Medicine, Baltimore, Maryland, discusses how lessons from external beam radiation therapy can guide adaptive dosing strategies in theranostics to improve tumor control while balancing toxicity.
Ana Kiess, MD, PhD, Johns...
02/12/2026
Radiopharmaceutical Education Institute
Robert Flavell, MD, PhD, UCSF
Videos
2025 ATA Guideline Updates for Differentiated Thyroid Cancer: What Oncologists Need to Know
02/12/2026
Robert Flavell, MD, PhD
Robert Flavell, MD, PhD, reviews the 2025 ATA guidelines for differentiated thyroid cancer, highlighting updated risk stratification, refined recommendations for radioactive iodine use, expanded use of SPECT/CT imaging, and new guidance on...
Robert Flavell, MD, PhD, reviews the 2025 ATA guidelines for differentiated thyroid cancer, highlighting updated risk stratification, refined recommendations for radioactive iodine use, expanded use of SPECT/CT imaging, and new guidance on...
Robert Flavell, MD, PhD, reviews...
02/12/2026
Radiopharmaceutical Education Institute
Mustafa Basree, DO, University of Wisconsin
Videos
Personalized Dosimetry Guides 177Lu-PSMA-617 Therapy in Prostate Cancer
02/06/2026
Mustafa Basree, DO
Mustafa Basree, DO, discusses institutional experience using voxel-level, patient-specific dosimetry to personalize 177Lu-PSMA-617 dosing in patients with metastatic castration-resistant prostate cancer.
Mustafa Basree, DO, discusses institutional experience using voxel-level, patient-specific dosimetry to personalize 177Lu-PSMA-617 dosing in patients with metastatic castration-resistant prostate cancer.
Mustafa Basree, DO, discusses...
02/06/2026
Radiopharmaceutical Education Institute

Advancing Oncology Through Radiopharmaceutical Innovation

The Radiopharmaceutical Education Institute (RPEI) is dedicated to advancing the science and clinical integration of radiopharmaceutical therapies in oncology. Through accessible, expert-driven education and multidisciplinary dialogue, we aim to equip clinicians with the insight and evidence needed to inform treatment decisions and shape the future of radiopharmaceutical innovation in cancer care.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use